Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilbert B Copeland

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Metabolic Engineering|May 26, 2012
Computational tools for metabolic engineeringWilbert B Copeland, Bryan A Bartley, Deepak Chandran, et al.
Blood Advances|December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLAmer M Zeidan, Isaac Boss, C L Beach, et al.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Science (New York, N.Y.)|November 9, 2019
Increasing gender diversity in the STEM research workforceCarol W Greider, Jason M Sheltzer, Nancy C Cantalupo, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Metabolic Engineering|May 26, 2012
Computational tools for metabolic engineeringWilbert B Copeland, Bryan A Bartley, Deepak Chandran, et al.
Blood Advances|December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLAmer M Zeidan, Isaac Boss, C L Beach, et al.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Science (New York, N.Y.)|November 9, 2019
Increasing gender diversity in the STEM research workforceCarol W Greider, Jason M Sheltzer, Nancy C Cantalupo, et al.
Plos Medicine|November 4, 2020
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trialsSamuel A Danziger, Mark McConnell, Jake Gockley, et al.
Pageof 1